• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾源性系统性纤维化——一种进展迅速、导致残疾的疾病,治疗选择有限。

Nephrogenic systemic fibrosis--a rapidly progressive disabling disease with limited therapeutic options.

作者信息

Schieren Gisela, Wirtz Nikolaus, Altmeyer Peter, Rump Lars Christian, Weiner Stefan Markus, Kreuter Alexander

机构信息

Department of Nephrology, University Hospital, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.

出版信息

J Am Acad Dermatol. 2009 Nov;61(5):868-74. doi: 10.1016/j.jaad.2009.03.040.

DOI:10.1016/j.jaad.2009.03.040
PMID:19836645
Abstract

BACKGROUND

Nephrogenic systemic fibrosis (NSF) affects some patients on dialysis after gadolinium contrast agent-enhanced magnetic resonance imaging. It is characterized by progressive skin fibrosis of the extremities, sometimes including the trunk and internal organs.

METHODS

The clinical course of 10 patients with biopsy-proven NSF was analyzed retrospectively with regard to gadolinium exposition, disease onset, and progression of NSF with special emphasis on physical mobility and impact of different therapeutic approaches.

RESULTS

Despite physiotherapy and different additional therapeutic approaches (eg, immunosuppression, ultraviolet A-1 phototherapy, or extracorporal photopheresis) all patients developed progressive skin fibrosis of the lower extremities, sometimes including the trunk and arms. Kidney transplantation led to a slow improvement of skin lesions in one patient. Nine patients developed progressive joint contractures, and 8 patients became wheelchair bound within 12 months after disease onset and became dependent on the support of family members or a nursing service.

LIMITATIONS

Retrospective analysis in a relatively small number of patients is a limitation.

CONCLUSION

NSF appears to be a rapidly progressive disabling disease with limited therapeutic options.

摘要

背景

钆对比剂增强磁共振成像后,肾源性系统性纤维化(NSF)会影响一些透析患者。其特征为四肢进行性皮肤纤维化,有时累及躯干和内脏。

方法

回顾性分析10例经活检证实为NSF患者的临床病程,涉及钆暴露情况、疾病起病及NSF的进展,特别关注身体活动能力以及不同治疗方法的影响。

结果

尽管进行了物理治疗及不同的其他治疗方法(如免疫抑制、紫外线A-1光疗或体外光分离置换法),所有患者均出现下肢进行性皮肤纤维化,有时累及躯干和手臂。1例患者肾移植后皮肤病变缓慢改善。9例患者出现进行性关节挛缩,8例患者在疾病起病后12个月内需要依赖轮椅,并需家人或护理服务的支持。

局限性

对相对少数患者进行回顾性分析是一个局限。

结论

NSF似乎是一种进展迅速的致残性疾病,治疗选择有限。

相似文献

1
Nephrogenic systemic fibrosis--a rapidly progressive disabling disease with limited therapeutic options.肾源性系统性纤维化——一种进展迅速、导致残疾的疾病,治疗选择有限。
J Am Acad Dermatol. 2009 Nov;61(5):868-74. doi: 10.1016/j.jaad.2009.03.040.
2
Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: a single-center experience.6 例肾移植受者中复发性肾源性系统性纤维化:单中心经验。
J Am Acad Dermatol. 2010 Sep;63(3):389-99. doi: 10.1016/j.jaad.2009.10.038. Epub 2010 Jul 8.
3
Clinical improvement of nephrogenic systemic fibrosis after kidney transplantation.肾移植后肾源性系统性纤维化的临床改善
Clin Transplant. 2008 Nov-Dec;22(6):803-8. doi: 10.1111/j.1399-0012.2008.00886.x. Epub 2008 Aug 18.
4
Gadolinium-associated nephrogenic systemic fibrosis in a 9-year-old boy.一名9岁男孩的钆相关肾源性系统性纤维化
Pediatr Dermatol. 2009 Sep-Oct;26(5):579-82. doi: 10.1111/j.1525-1470.2008.00802.x.
5
UV-A1 therapy for nephrogenic systemic fibrosis.用于治疗肾源性系统性纤维化的UV-A1疗法。
Arch Dermatol. 2009 Oct;145(10):1170-4. doi: 10.1001/archdermatol.2009.245.
6
Ten-year experience with nephrogenic systemic fibrosis: case-control analysis of risk factors.肾源性系统性纤维化的十年经验:危险因素的病例对照分析
J Comput Assist Tomogr. 2009 Nov-Dec;33(6):819-23. doi: 10.1097/RCT.0b013e31819d68ed.
7
Nephrogenic systemic fibrosis: clinical picture and treatment.肾源性系统性纤维化:临床表现与治疗
Radiol Clin North Am. 2009 Sep;47(5):833-40, vi. doi: 10.1016/j.rcl.2009.05.004.
8
Nephrogenic systemic fibrosis: report of an additional case with granulomatous inflammation.肾源性系统性纤维化:1例伴有肉芽肿性炎症的新增病例报告。
Am J Dermatopathol. 2010 Feb;32(1):71-5. doi: 10.1097/DAD.0b013e3181b0b859.
9
The evolution of osseous metaplasia in localized cutaneous nephrogenic systemic fibrosis: a case report.局限性皮肤型肾源性系统性纤维化中骨化生的演变:一例报告
Am J Dermatopathol. 2009 Oct;31(7):674-81. doi: 10.1097/DAD.0b013e3181a1fb55.
10
Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction.肾源性系统性纤维化:一种与钆相关的肾功能不全患者的纤维化疾病。
Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii66-9. doi: 10.1136/ard.2008.102475.

引用本文的文献

1
Dermatological Manifestations in Patients With Chronic Kidney Disease: A Review.慢性肾脏病患者的皮肤表现:综述
Cureus. 2024 Jan 14;16(1):e52253. doi: 10.7759/cureus.52253. eCollection 2024 Jan.
2
The Clinical Manifestations and Efficacy of Different Treatments Used for Nephrogenic Systemic Fibrosis: A Systematic Review.肾源性系统性纤维化不同治疗方法的临床表现及疗效:一项系统评价
Int J Nephrol Renovasc Dis. 2023 Jan 12;16:17-30. doi: 10.2147/IJNRD.S392231. eCollection 2023.
3
Nephrogenic systemic fibrosis: A frivolous entity.
肾源性系统性纤维化:一个无足轻重的病症。
World J Nephrol. 2021 May 25;10(3):29-36. doi: 10.5527/wjn.v10.i3.29.
4
Manganese dioxide nanosheets: from preparation to biomedical applications.二氧化锰纳米片:从制备到生物医学应用。
Int J Nanomedicine. 2019 Jul 3;14:4781-4800. doi: 10.2147/IJN.S207666. eCollection 2019.
5
A unique case of nephrogenic systemic fibrosis from gadolinium exposure in a patient with normal eGFR.一名估算肾小球滤过率(eGFR)正常的患者因接触钆而发生肾源性系统性纤维化的罕见病例。
BMJ Case Rep. 2017 Oct 11;2017:bcr-2017-221016. doi: 10.1136/bcr-2017-221016.
6
Cutaneous manifestations of ESRD.终末期肾病的皮肤表现。
Clin J Am Soc Nephrol. 2014 Jan;9(1):201-18. doi: 10.2215/CJN.05900513. Epub 2013 Oct 10.
7
Scleroderma mimics.硬皮病的类似疾病。
Curr Rheumatol Rep. 2012 Feb;14(1):39-46. doi: 10.1007/s11926-011-0220-8.
8
Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases.肾源性系统性纤维化:408例经活检确诊病例的综述。
Indian J Dermatol. 2011 Jan;56(1):65-73. doi: 10.4103/0019-5154.77556.
9
Nephrogenic systemic fibrosis: a brief review.肾源性系统性纤维化:简要综述。
Indian J Dermatol. 2011 Jan;56(1):54-8. doi: 10.4103/0019-5154.77554.